Investments
217Portfolio Exits
84
Want to inform investors similar to Downsview Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Downsview Capital Investments
217 Investments
Downsview Capital has made 217 investments. Their latest investment was in Cascadian Therapeutics as part of their PIPE on February 2, 2011.
Downsview Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
2/11/2011 | PIPE | Cascadian Therapeutics | $0.15M | Yes | Atoll Asset Management, AXA, Bristol Capital Advisors, Cantara, Cowen, Dafna Capital Management, Deerfield Management, Downsview Capital, Evolution Capital Management, Global Capital Partners, Heights Capital Management, Highbridge Capital Management, Hudson Bay Capital Management, Iroquois Capital Group, JGB Management, Paramount BioCapital Asset Management, RG Capital, Rockmore Capital, Tail Wind Fund, and Undisclosed Venture Investors | |
8/22/2008 | PIPE - II | Arotech | $5M | No | ||
8/22/2008 | PIPE - II | LightPath Technologies | $2.93M | No | ||
8/8/2008 | PIPE - II | |||||
8/5/2008 | PIPE |
Date | 2/11/2011 | 8/22/2008 | 8/22/2008 | 8/8/2008 | 8/5/2008 |
|---|---|---|---|---|---|
Round | PIPE | PIPE - II | PIPE - II | PIPE - II | PIPE |
Company | Cascadian Therapeutics | Arotech | LightPath Technologies | ||
Amount | $0.15M | $5M | $2.93M | ||
New? | Yes | No | No | ||
Co-Investors | Atoll Asset Management, AXA, Bristol Capital Advisors, Cantara, Cowen, Dafna Capital Management, Deerfield Management, Downsview Capital, Evolution Capital Management, Global Capital Partners, Heights Capital Management, Highbridge Capital Management, Hudson Bay Capital Management, Iroquois Capital Group, JGB Management, Paramount BioCapital Asset Management, RG Capital, Rockmore Capital, Tail Wind Fund, and Undisclosed Venture Investors | ||||
Sources |
Downsview Capital Portfolio Exits
84 Portfolio Exits
Downsview Capital has 84 portfolio exits. Their latest portfolio exit was Antares Pharma on May 24, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
5/24/2022 | Acq - P2P | 5 | |||
12/19/2019 | Acquired | 6 | |||
3/9/2018 | Acq - P2P | 4 | |||
Date | 5/24/2022 | 12/19/2019 | 3/9/2018 | ||
|---|---|---|---|---|---|
Exit | Acq - P2P | Acquired | Acq - P2P | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 5 | 6 | 4 |
Downsview Capital Acquisitions
1 Acquisition
Downsview Capital acquired 1 company. Their latest acquisition was Ventyx on January 18, 1999.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
1/18/1999 | Acquired |
Date | 1/18/1999 |
|---|---|
Investment Stage | |
Companies | |
Valuation | |
Total Funding | |
Note | Acquired |
Sources |
Downsview Capital Team
1 Team Member
Downsview Capital has 1 team member, including current President, Mitchell P. Kopin.
Name | Work History | Title | Status |
|---|---|---|---|
Mitchell P. Kopin | President | Current |
Name | Mitchell P. Kopin |
|---|---|
Work History | |
Title | President |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
